

FOR IMMEDIATE RELEASE

Researchers to Present Data on Immunovaccine's Infectious Disease Pipeline at Three International Conferences

Presentations at RSV16, World Vaccine Congress Europe and IDWeek Conferences Highlight Company's Progress in Using DepoVax™-based Agents to Address Respiratory Syncytial Virus (RSV) and Life-Threatening Malaria

Halifax, Nova Scotia, September 23, 2016 – Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX: IMV; OTCQX: IMMVF), a clinical-stage vaccine and immunotherapy company, today announced planned data presentations at upcoming scientific meetings in conjunction with collaborators at [VIB, the Flemish life sciences research institute](#), and the [Canadian Center for Vaccinology \(CCfV\)](#). These presentations will focus on DPX-RSV, Immunovaccine's lead infectious disease candidate in development for the prevention of respiratory syncytial virus (RSV).

In addition, researchers will present the first results from the Company's preclinical collaboration with the University of [Edinburgh's Center for Immunity, Infection and Evolution](#) (CIIE) on life-threatening malaria.

Details for the presentations are as follows:

Presentation at 10th International Respiratory Syncytial Virus Symposium (RSV16), September 28-October 1, 2016 in Patagonia, Argentina

Session: Poster Session 1; Poster 393
Session Date: September 28-29, 2016
Session Location: Llao Llao Hotel, Tronador Room in Bariloche, Argentina
Session Time: Afternoon of September 28 - Afternoon of September 29
Presentation Title: "Live Cell Imaging of Antibody Dependent Phagocytosis and Trogocytosis of RSV And Influenza Virus Infected Cells"

Presentations at World Vaccine Congress Europe, October 10-12, 2016 in Barcelona, Spain

Session: Respiratory
Session Date: Monday, October 10, 2016
Session Location: Fairmount Rey Juan Caros, Barcelona, Spain
Session Time: 4:45 PM CEST

Presentation Title: “Preclinical and Clinical development of a new HRSV vaccine based on the Small Hydrophobic protein that instructs macrophages to clear infected cells”

Session: Poster Sessions 1 and 2

Session Date: Monday, October 10 - Tuesday, October 11, 2016

Session Location: Fairmount Rey Juan Caros, Barcelona, Spain

Session Time: 1:15 - 4:45 PM CEST

Presentation Title: “Single dose immunization with DepoVax™ induces potent, long-lasting antibodies to PfEMP1: a novel malaria vaccine approach”

Presentation at IDWeek, October 26-30, 2016 in New Orleans, Louisiana

Session: Clinical Infectious Diseases: Respiratory Infections

Session Date: Friday, October 28, 2016

Session Time: 12:30 PM - 2:00 PM CT

Session Location: New Orleans Convention Center Poster Hall

Presentation Title: “A Phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SH antigen and a novel adjuvant DepoVax™, or SH antigen co-administered with aluminum hydroxide, or placebo to healthy adults ≥50-64 years of age”

More information on the [RSV16, World Vaccine Congress Europe](#) and [IDWeek 2016](#) abstracts can be found on the conference websites.

About Immunovaccine

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com

Forward-looking Statement

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the

estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals and the matters discussed under “Risk Factors and Uncertainties” in Immunovaccine’s Annual Information Form filed on March 29, 2016. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

###

Contacts for Immunovaccine:

MEDIA

Mike Beyer, Sam Brown Inc.

T: (312) 961-2502 E: mikebeyer@sambrown.com

INVESTOR RELATIONS

Kimberly Stephens, Chief Financial Officer

T: (902) 492-1819 E: kstephens@imvaccine.com